Abstract
This review analyzes the research results of additional effects and mechanisms of action of sugar-reducing drugs. Hence it has been suggested that asymmetric dimethylarginine may be a target molecule for metformin, vildagliptin, and combinations thereof. (For citation: Urakov AL, Gurevich KG, Sorokina IA, et al. Metformin and vildagliptin combination: a new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2. Reviews on Clinical Pharmacology and Drug Therapy. 2018;16(2):5-12. doi: 10.17816/RCF1625-12).
Highlights
В данном обзоре литературы проведен анализ результатов исследований в области изучения дополнительных эффектов и механизмов действия сахароснижающих препаратов
It has been suggested that asymmetric dimethylarginine may be a target molecule for metformin, vildagliptin, and combinations thereof
Воздействие комбинации препаратов метформина и вилдаглиптина на эндогенный регулятор активности eNOS3 — уровень АДМА —
Summary
В данном обзоре литературы проведен анализ результатов исследований в области изучения дополнительных эффектов и механизмов действия сахароснижающих препаратов. Что асимметричный диметиларгинин может быть молекулой-мишенью для метформина, вилдаглиптина, а также их комбинации. For citation: Urakov AL, Gurevich KG, Sorokina IA, et al Metformin and vildagliptin combination: a new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.